Background
==========

Acute myeloid leukemia (AML) is a malignant clonal disorder distinguished by differentiation block of myeloid and accumulation of abnormal myeloid progenitors in the bone marrow (BM) and blood \[[@b1-medscimonit-25-4952]\]. In adults, AML is the most common form of acute leukemia \[[@b2-medscimonit-25-4952]\], and the incidence increases with age \[[@b3-medscimonit-25-4952]\]. Patients may present with bleeding, anemia, and infection complications due to bone marrow failure, but often only have fatigue on initial presentation \[[@b3-medscimonit-25-4952]--[@b5-medscimonit-25-4952]\]. The evolving molecular genetics facilitate discernment of AML prognostic indicators, especially in cytogenetic results and molecular abnormalities \[[@b6-medscimonit-25-4952]\].

In the past decade, non-coding RNAs (ncRNAs), involving microRNAs, small interfering RNAs (siRNAs), long non-coding RNAs (lncRNAs), and pseudogenes, have attracted intense attention \[[@b7-medscimonit-25-4952]\]. There is an increasing focus on the relationship between non-coding RNA and cancer, especially as a diagnostic and prognostic biomarker of cancer from early detection to monitor recurrence or treatment progression \[[@b8-medscimonit-25-4952]\]. Pseudogenes were defined as 'junk DNA' that no longer possess biological functions due to nonsense or frameshift mutations in coding genes, whereas some pseudogene-derived RNAs have been shown to have unique regulatory roles, and some pseudogene fragments can be translated \[[@b9-medscimonit-25-4952]\]. Increasing evidence indicates that pseudogenes show important biological functions in human cancers \[[@b10-medscimonit-25-4952]\]. Kong et al. demonstrated that the pseudogene *PDIA3P1* is overexpressed in HCC tissues and is associated with tumor size and TNM stage, and knockdown of *PDIA3P1* decreases HCC cell proliferation and promotes apoptosis \[[@b11-medscimonit-25-4952]\].

The*POU* family possesses a *POU* DNA-binding domain, and*Oct-4* is one of the transcription factors of the family. As a master transcription factor for pluripotent cell self-renewal,*Oct-4* plays a critical role in the embryonic development of mammals \[[@b12-medscimonit-25-4952]\]. Alternative splicing of *Oct-4* produces 3 isoforms: *Oct-4A*,*Oct-4B,* and *Oct-4B1* \[[@b13-medscimonit-25-4952]\].*Oct-4A (Oct-4)* can maintain stem cell self-renewal, while *Oct-4B* cannot \[[@b14-medscimonit-25-4952]\]. Two of the 6 highly homologous pseudogenes of human*Oct-4* -- *Oct-4-pg1* and *Oct-4-pg5 --* were found to be transcribed in somatic cancers \[[@b15-medscimonit-25-4952]\]. Overexpression of *POU5F1B (Oct-4-pg1)* is reported in gastric cancer and is associated with unfavorable prognosis in stage IV patients \[[@b16-medscimonit-25-4952]\]. The aim of this study was to evaluate expression of *POU5F1B* in patients with an initial diagnosis of AML, as well as to explore the correlation between *POU5F1B* and AML.

Material and Methods
====================

Patient samples
---------------

The study was subject approved by the Institutional Ethics Committee of the Affiliated People's Hospital of Jiangsu University. Bone marrow samples were collected from 214 adults, including 39 healthy donors and 175 newly diagnosed AML patients before chemotherapy. The patients were diagnosed according to the WHO and French-American-British (FAB) classification \[[@b17-medscimonit-25-4952],[@b18-medscimonit-25-4952]\]. All participants signed written informed consent. Previous articles have described treatment protocols for AML patients \[[@b19-medscimonit-25-4952]\].

RNA isolation, reverse transcription, and RQ-PCR
------------------------------------------------

Lymphocyte Separation Medium (TBD Sciences, Tianjin, China) was used to separate bone marrow mononuclear cells (BMNCs). Trizol reagent (Invitrogen, Carlsbad, CA) was used to separated total RNA. We used 10 mM of dNTPs, 2 μg of total RNA from each sample, 10 μM of random hexamers, 80 U of RNase inhibitor, and 200 U of MMLV reverse transcriptase (MBI Fermentas, Hanover, MA) and reverse-transcribed them into single-stranded complementary DNA (cDNA), and then stored them at −20°C.

We used a 7500 Thermal cycler (Applied Biosystems, CA) to perform RQ-PCR. The forward primer used for *POU5F1B* transcript detection was 5′-GCGATCAAGCAGCGACTA-3′, and the reverse primer was 5′-AGGGAAAGGGACTGAGGAG -3′. *POU5F1B* transcript level detection was quantified by RT-qPCR as follows: 95°C for 30 s, and then 40 cycles at 95°C for 5 s, 58.1°C for 30 s, 72°C for 30 s, and 80°C for 31 s to collect fluorescence, and finally, the melting program at 95°C for 15 s, 60°C for 60 s, 95°C for 15 s, and 60°C for 15 s. The amount of *POU5F1B* transcript was calculated by analyzing expression of the housekeeper gene *ABL* using 2^−ΔΔCT^ method.

Gene mutation detection
-----------------------

Mutations of *DNMT3A, N/K-RAS, NPM1, c-KIT, IDH2 R140, IDH1/2, U2AF1, and SRSF2* were detected by PCR and high-resolution melting analysis (HRMA) \[[@b20-medscimonit-25-4952]--[@b24-medscimonit-25-4952]\]. Mutations of *CEBPA* and *FLT3-ITD* genes and all positive samples were detected in genomic DNA by PCR and direct sequencing \[[@b25-medscimonit-25-4952]\].

Statistical analyses
--------------------

SPSS22.0 software was used for statistical analysis. *P*\<0.05 was considered statistically significant for all analyses. Continuous variables between the 2 groups were compared using the Mann-Whitney U test. The Fisher exact test or Pearson chi-square analysis was used, as appropriate, to compare categorical variables across groups. The diagnostic accuracy of *POU5F1B* expression in discriminating AML patients from normal controls was calculated by ROC curve and area under the ROC curve (AUC). Kaplan-Meier curves were used to estimate the effect of *POU5F1B* expression on survival, and Cox regression models were used to independently assess the prognostic value of *POU5F1B* expression.

Results
=======

*POU5F1B* expression in controls and AML patients
-------------------------------------------------

Assessment of*POU5F1B* transcript levels in AML patients (0--246.92, median 0.0536) detected underexpression compared to controls (0--217.99, median 0.7991) (*P*\<0.001, [Figure 1](#f1-medscimonit-25-4952){ref-type="fig"}). Moreover, the level of *POU5F1B* expression was lower in non-APL AML patients and in intermediate-risk AML patients (*P*\<0.001 and *P*\<0.001, [Figure 1](#f1-medscimonit-25-4952){ref-type="fig"}).

Diagnostic accuracy of *POU5F1B* expression
-------------------------------------------

ROC was utilized to analyze the differentiating value of *POU5F1B* expression. It indicated that *POU5F1B* can act as a potential marker to distinguish whole-cohort AML patients from controls, with an AUC of 0.682 (95%CI: 0.579--0.786, *P*\<0.001). Meanwhile, the level of *POU5F1B* expression might be used to segregate non-APL AML (AUC=0.683, 95%CI: 0.579--0.786,*P*\<0.001) from normal controls, and a similar result was found in the intermediate-risk group (AUC=0.663, 95%CI: 0.556--0.770,*P*=0.003) ([Figure 2](#f2-medscimonit-25-4952){ref-type="fig"}).

Association of *POU5F1B* expression with clinical and laboratory features in AML
--------------------------------------------------------------------------------

We divided the AML patients into 2 groups using a cutoff value of mean minus 2SD obtained in normal controls: *POU5F1B^high^* (\>1.005) and *POU5F1B^low^* (≤1.005). None of these differences between the 2 groups were statistically significant, such as sex, age, white blood cells (WBC), hemoglobin (HB), platelets (PLT), BM blasts, FAB subtypes, karyotypes, and gene mutations. However, the results, as shown in [Table 1](#t1-medscimonit-25-4952){ref-type="table"}, indicated that the CR of *POU5F1B^high^* patients was significantly higher than that of *POU5F1B^low^* patients (*P*=0.012, [Table 1](#t1-medscimonit-25-4952){ref-type="table"}). When M3 patients were excluded, the comparison of laboratory characteristics and clinical data between the 2 groups ([Table 1](#t1-medscimonit-25-4952){ref-type="table"}), patients with lower expression of *POU5F1B* had significantly higher WBC than those with higher expression of *POU5F1B* (20.2×10^9^ *vs.* 4.6×10^9^ L^−1^, *P*=0.021). As with whole AML, in non-APL and intermediate-risk AML patients, the CR was strikingly higher in *POU5F1B^high^* patients than in *POU5F1B^low^* (*P*=0.012 and *P*=0.027, [Tables 1](#t1-medscimonit-25-4952){ref-type="table"}, [2](#t2-medscimonit-25-4952){ref-type="table"}). The intermediate-risk AML patients with lower *POU5F1B* were older (P=0.038, [Table 2](#t2-medscimonit-25-4952){ref-type="table"}).

Prognostic value of *POU5F1B* in AML
------------------------------------

OS and leukemia-free survival (LFS) were estimated according to Kaplan-Meier methods. OS (*P*=0.019, median 7 *vs.* 17 months; *P*=0.007, median 5 *vs.* 12 months, respectively) was significantly worse in the whole-cohort AML patients and non-APL AML patients with low *POU5F1B* expression. Kaplan-Meier analysis showed that intermediate-risk AML patients with *POU5F1B* low expression had significantly shorter OS (*P*=0.046, median 4.5 *vs.* 12 months, [Figure 3F](#f3-medscimonit-25-4952){ref-type="fig"}). There was no significant association between *POU5F1B* expression and LFS (*P*=0.510, *P*=0.131, and *P*=0.672, respectively) among the 3 AML groups ([Figure 3](#f3-medscimonit-25-4952){ref-type="fig"}).

In multivariate analyses, *POU5F1B* overexpression remained a significant favorable prognostic factor for OS (*P*=0.014 and *P*=0.023) in non-APL and intermediate-risk AML patients. However, improved OS was not observed among whole-cohort AML patients ([Table 3](#t3-medscimonit-25-4952){ref-type="table"}).

Discussion
==========

*Oct-4* was reported to be overexpressed in several types of cancers, such as bladder cancer \[[@b26-medscimonit-25-4952]\], hepatocellular carcinoma \[[@b27-medscimonit-25-4952]\], primary endometrioid endometrial and ovarian carcinomas \[[@b28-medscimonit-25-4952]\], and non-small-cell lung cancer \[[@b29-medscimonit-25-4952]\]. *Oct-4* high expression in AML was a common molecular event, and AML patients with high expression of *Oct-4* showed a shorter overall survival rate \[[@b30-medscimonit-25-4952]\]. *POU5F1B* was reported as a susceptibility gene in breast cancer \[[@b31-medscimonit-25-4952]\], prostate cancer \[[@b32-medscimonit-25-4952]\], and gastric cancer \[[@b33-medscimonit-25-4952]\]. Hayashi et al. reported that overexpression of *POU5F1B* induces overexpression of GC cell growth factors, which in turn promotes cell proliferation and inhibits apoptosis \[[@b16-medscimonit-25-4952]\].*POU5F1B* promotes HCC proliferation by activating AKT, and patients with high*POU5F1B* level have shorter survival times \[[@b34-medscimonit-25-4952]\]. HPV integrated in *POU5F1B* in cervical tumor cells survives during radiotherapy and may lead to resistance to radiation therapy \[[@b35-medscimonit-25-4952]\]. To date, abnormal expression of a few pseudogenes in AML have been reported, including *Vim2p, DUSP5P1,* and*BMI1P1* \[[@b36-medscimonit-25-4952]--[@b38-medscimonit-25-4952]\]. However, there has been no research focused on pseudogene *POU5F1B* in AML. In this study,*POU5F1B* transcript was expressed at lower levels in AML patients compared with the control group. ROC analysis revealed that low *POU5F1B* expression is a prospective biomarker for use in discriminating AML patients, including non-APL AML and intermediate-risk AML patients, from healthy controls. AML patients with high WBC count have a particularly poor prognosis \[[@b39-medscimonit-25-4952]\]. Similarly, our finding suggested that non-APL AML patients with lower *POU5F1B* expression had higher WBC counts and worse survival.

Furthermore, CR rates and OS were significantly better in the*POU5F1B^high^* group than in the *POU5F1B^low^* group in total AML, non-APL, and intermediate-risk AML patients. Multivariate analyses demonstrated that *POU5F1B* was an independent prognostic factor for OS in non-APL and intermediate-risk AML patients. Collectively, these results showed that detecting the expression of the *POU5F1B* transcript in AML patients, especially non-APL AML and intermediate-risk patients, might have important prognostic and curative implications. *POU5F1B* expression has no significant correlation with LFS, and we considered that it was caused by the differences in consolidation and intensification therapy. A more comprehensive study including all the subgroups is needed, such as different treatment and age groups, CR and non-CR groups, and the cases need to be expanded.

Competing endogenous RNA (ceRNAs) are RNA transcripts, including long non-coding RNAs, pseudogenes, and circular RNAs \[[@b40-medscimonit-25-4952]\], and they regulate each other by competing to bind to shared microRNA (miRNA) recognition elements (MREs) \[[@b41-medscimonit-25-4952]\]. Pseudogenes show sequence similarity to their parental genes, with many identical MREs in its sequence \[[@b42-medscimonit-25-4952]\]. Pseudogenes regulate their parental transcripts by competing for shared miRNAs \[[@b43-medscimonit-25-4952]\]. A number of studies have found that ceRNAs abundance and activity are underexpressed in cancer; therefore, these ceRNAs may be potential diagnostic biomarkers in cancer \[[@b44-medscimonit-25-4952]\]. Previous studies have reported that 2 pseudogenes of *HMGA1* -- *HMGA1P6* and *HMGA1P7* -- act as competitive endogenous RNA decoys for carcinogenesis genes *HMGA1, H19,* and *Igf2*, and pseudogene overexpression increases oncogenes levels, inhibiting their mRNA suppression by miRNAs that target *HMGA1P7* gene \[[@b45-medscimonit-25-4952]\]. Scarola et al. showed that the lncRNA produced by *Oct-4-pg4* (X-linked*Oct-4* pseudogene) during transcription is overexpressed during mESC differentiation and forms a complex with *SUV39H1 HMTase* to regulate the ancestral *Oct-4* gene promoter, resulting in *Oct-4* gene silence and reduced mESC self-renewal \[[@b46-medscimonit-25-4952]\]. In hepatocellular carcinoma cells (HCC) and endometrial carcinoma, *Oct-4-pg4* and *pg5* function as miRNA sponges protecting *Oct-4* transcript by competing with miR-145 \[[@b47-medscimonit-25-4952]\]. To date, the function of the pseudogene *POU5F1B* in AML remains largely unknown. Combined with the expression of *Oct-4* in AML, an interesting pattern emerges: the transcript levels of *Oct-4* and *POU5F1B* showed the exact opposite trend. We anticipate that the pseudogene-derived lncRNAs may regulate the promoter of the parental gene *Oct-4*, resulting in reduced*Oct-4* gene silencing. *POU5F1B* was found to have 95% homology with *Oct-4* \[[@b48-medscimonit-25-4952]\]; therefore, *POU5F1B* may serve as ceRNA, allowing *Oct-4* to evade miRNA inhibition. More research on this topic is needed, including *in vivo* and *in vitro* functional assays, correlation analysis with *Oct-4* and *POU5F1B* expression levels, prediction and detection of pseudogene-derived lncRNAs and*POU5F1B-*targeted miRNAs, and stemness potential assays.

Conclusions
===========

Expression of the *POU5F1B* transcript is significantly decreased in AML patients and is associated with unfavorable clinical variables and poor prognosis. *POU5F1B* has promise as a potential novel biomarker and target for future therapy.
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![Relative expression levels of*POU5F1B* in AML patients and controls. The transcript level of *POU5F1B* in controls, whole-cohort AML patients, non-APL patients, and intermediate-risk AML patients were evaluated by RQ-PCR. Horizontal lines represent the median level of *POU5F1B* expression in each group.](medscimonit-25-4952-g001){#f1-medscimonit-25-4952}

![ROC curve analysis for distinguishing AML patients from controls. (**A**) Whole AML patients; (**B**) Non-APL patients; (**C**) Intermediate-risk AML.](medscimonit-25-4952-g002){#f2-medscimonit-25-4952}

![Differences in leukemia-free survival and overall survival between the *POU5F1B*^high^ group and the *POU5F1B^low^* group were estimated using to Kaplan-Meier method. (**A**) LFS for whole AML patients; (**B**) OS for whole AML patients; (**C**) LFS for non-APL patients; (**D**) OS for non-APL patients; (**E**) LFS for intermediate-risk patients; (**F**) OS for intermediate-risk patients.](medscimonit-25-4952-g003){#f3-medscimonit-25-4952}

###### 

Comparison of clinical and laboratory features between whole-cohort AML and non-APL AML patients with low and high expression.

  Patient parameters                   Whole-cohort AML     Non-APL AML                                                            
  ------------------------------------ -------------------- -------------------- ------- -------------------- -------------------- -------
  Sex, Male/Female                     90/55                20/10                0.683   75/43                15/9                 1.000
  Median age, years (range)            57 (20--93)          54 (21--83)          0.105   61 (20--93)          57 (28--83)          0.135
  Median WBC, ×10^9^/L (range)         16.3 (0.4--528.0)    5.5 (0.3--203.6)     0.103   20.2 (0.4--528.0)    4.6 (0.8--203.6)     0.021
  Median hemoglobin, g/L (range)       77.5 (32.0--144.0)   77.0 (34.0--131.0)   0.893   76.0 (32.0--144.0)   77.5 (34.0--131.0)   0.963
  Median platelets, ×10^9^/L (range)   40.0 (3.0--447.0)    46.5 (4.0--415.0)    0.937   42.0 (3.0--447.0)    50.0 (4.0--415.0)    0.714
  BM blasts,% (range)                  46.7 (3.0--99.0)     37.5 (1.0--93.0)     0.203   56.5 (10.5--99.0)    43.0 (6.0--93.0)     0.193
  CR (+/−)                             50/83                18/10                0.012   29/78                13/10                0.012
   FAB                                                                           0.956                                             0.904
   M0                                  2                    1                            2                    1                    
   M1                                  10                   1                            10                   1                    
   M2                                  56                   13                           56                   13                   
   M3                                  27                   6                            --                   --                   
   M4                                  29                   5                            29                   5                    
   M5                                  16                   3                            17                   3                    
   M6                                  5                    1                            5                    1                    
  Karyotype classification                                                       0.353                                             0.329
   Favorable                           37                   8                            12                   2                    
   Intermediate                        78                   20                           77                   20                   
   Poor                                21                   1                            21                   1                    
   No data                             9                    1                            8                    1                    
  Karyotype                                                                      0.320                                             0.209
   Normal                              57                   18                           56                   18                   
   t(8;21)                             9                    2                            9                    2                    
   t(15;17)                            25                   6                            0                    0                    
   +8                                  6                    0                            6                    0                    
   Others                              23                   1                            23                   1                    
   Complex                             16                   2                            16                   2                    
   No data                             9                    1                            8                    1                    
  Gene mutation                                                                                                                    
   *CEBPA (+/−)*                       14/106               3/23                 1.000   14/85                3/18                 1.000
   *NPM1 (+/−)*                        13/107               4/22                 0.506   13/86                4/17                 0.496
   *FLT3-ITD (+/−)*                    16/104               2/24                 0.742   13/86                2/19                 1.000
   *c-KIT (+/−)*                       6/114                1/25                 1.000   5/94                 1/20                 1.000
   *NRAS* or *KRAS (+/−)*              7/113                3/23                 0.384   7/92                 3/18                 0.377
   *IDH1/2 (+/−)*                      6/114                1/25                 1.000   6/93                 1/20                 1.000
   *IDH2 R140(+/−)*                    4/116                1/25                 1.000   4/95                 1/21                 1.000
   *DNMT3A (+/−)*                      10/110               0/26                 0.209   10/89                0/21                 0.206
   *U2AF1 (+/−)*                       5/115                1/25                 1.000   5/94                 1/20                 1.000
   *SRSF2 (+/−)*                       7/117                0/26                 0.605   7/94                 0/21                 0.600

###### 

Comparison of clinical and laboratory features between patients with intermediate-risk AML low and high expression.

  Patient parameters                   Intermediate-risk AML                        
  ------------------------------------ ----------------------- -------------------- -------
  Sex, Male/Female                     49/29                   13/7                 1.000
  Median age, years (range)            61 (20--93)             57 (21--83)          0.038
  Median WBC, ×10^9^/L (range)         21.3 (0.4--528.0)       7.7 (0.3--203.6)     0.129
  Median hemoglobin, g/L (range)       81.5 (32.0--144.0)      77.5 (34.0--131.0)   0.988
  Median platelets, ×10^9^/L (range)   42.5 (3.0--399.0)       52.5 (4.0--415.0)    0.547
  BM blasts,% (range)                  55.0 (21.5--99.0)       48.5 (6.0--93.0)     0.506
  CR (+/−)                             20/52                   11/8                 0.027
  FAB                                                                               0.883
   M0                                  1                       1                    
   M1                                  6                       1                    
   M2                                  39                      9                    
   M3                                  1                       0                    
   M4                                  17                      5                    
   M5                                  11                      3                    
   M6                                  3                       1                    
  Gene mutation                                                                     
   *CEBPA (+/−)*                       11/57                   3/14                 1.000
   *NPM1 (+/−)*                        11/57                   4/13                 0.487
   *FLT3-ITD (+/−)*                    10/58                   2/15                 1.000
   *c-KIT (+/−)*                       1/67                    1/16                 0.362
   *NRAS* or *KRAS (+/−)*              7/61                    3/14                 0.411
   *IDH1/2 (+/−)*                      5/63                    1/16                 1.000
   *IDH2 R140(+/−)*                    3/65                    1/16                 1.000
   *DNMT3A (+/−)*                      9/59                    0/17                 0.194
   *U2AF1 (+/−)*                       4/64                    1/16                 1.000
   *SRSF2 (+/−)*                       6/64                    0/17                 0.593

###### 

Multivariate analyses of prognostic factors for overall survival in non-APL and intermediate-risk AML cases.

  Prognostic factors                                                     Non-APL AML             Intermediate-risk AML                           
  ---------------------------------------------------------------------- ----------------------- ----------------------- ----------------------- -------
  Sex (Male *vs.* Female)                                                1.136 (0.713--1.812)    0.591                   0.876 (0.512--1.498)    0.629
  Age (≤60 *vs.* \>60 years)                                             1.384 (0.905--2.117)    0.134                   1.116 (0.642--1.939)    0.698
  WBC (≥30×10^9^/L *vs.* \<30×10^9^/L)                                   1.209 (0.776--1.884)    0.401                   1.499 (0.882--2.548)    0.134
  PLT (100×10^9^/L *vs.* 100×10^9^/L)                                    1.340 (0.766--2.343)    0.305                   1.074 (0.528--2.184)    0.845
  Karyotypic classifications (favorable *vs.* intermediate *vs.* poor)   1.683 (1.251--2.266)    0.001                   --                      --
  *POU5F1B* expression (high *vs.* low)                                  0.453 (0.241--0.852)    0.014                   0.448 (0.225--0.896)    0.023
   *IDH1/2* mutation (mutant *vs.* wild-type)                            4.470 (1.860--10.740)   0.001                   5.732 (2.197--14.960)   0.000
   *IDH2 R140* mutation (mutant *vs.* wild-type)                         0.650 (0.118--3.585)    0.621                   0.636 (0.102--3.948)    0.627
   *U2AF1* mutation (mutant *vs.* wild-type)                             2.452 (1.013--5.931)    0.047                   2.206 (0.831--5.858)    0.112
   *SRSF2* mutation (mutant *vs.* wild-type)                             1.339 (0.540--3.321)    0.529                   2.032 (0.766--5.390)    0.154
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